1. Young, G, Callaghan, M, Dunn, A, et al. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol 2018; 11: 835–846.
Google Scholar | Crossref | Medline2. Srivastava, A, Santagostino, E, Dougall, A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26: 1–158.
Google Scholar | Crossref | Medline3. Fischer, K, Bom, JG, Mauser-Bunschoten, EP, et al. Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia 2005; 11: 43–48.
Google Scholar | Crossref | Medline4. Franchini, M, Mannucci, P. Hemophilia A in the third millennium. Blood Rev 2013; 27: 179–184.
Google Scholar | Crossref | Medline | ISI5. Lieuw, K . Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med 2017; 8: 67–73.
Google Scholar | Crossref | Medline6. Ljung, RCR . Prevention and management of bleeding episodes in children with hemophilia. Paediatr Drugs 2018; 20: 455–464.
Google Scholar | Crossref | Medline7. Walsh, CE, Jiménez-Yuste, V, Auerswald, G, et al. The burden of inhibitors in haemophilia patients. Thromb Haemost 2016; 116: S10–17.
Google Scholar | Crossref | Medline8. Rocino, A, Franchini, M, Coppola, A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med 2017; 6: 46.
Google Scholar | Crossref9. Carcao, M, Escuriola-Ettingshausen, C, Santagostino, E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019; 25: 676–684.
Google Scholar | Crossref | Medline10. Garagiola, I, Palla, R, Peyvandi, F. Risk factors for inhibitor development in severe hemophilia A. Thromb Res 2018; 168: 20–27.
Google Scholar | Crossref | Medline11. van den Berg, HM, Fischer, K, Carcao, M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood 2019; 134: 317–320.
Google Scholar | Crossref | Medline12. Sampei, Z, Igawa, T, Soeda, T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8: e57479.
Google Scholar | Crossref | Medline13. Mancuso, ME, Mahlangu, JN, Pipe, SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021; 397: 630–640.
Google Scholar | Crossref | Medline14. Coppola, A, Di Capua, M, Di Minno, MN, et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183–195.
Google Scholar | Crossref | Medline15. Oldenburg, J, Mahlangu, JN, Kim, B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809–818.
Google Scholar | Crossref | Medline | ISI16. Carcao, M, Mancuso, ME, Young, G, et al. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol 2021; 14: 143–148.
Google Scholar | Crossref | Medline17. Ljung, R, Auerswald, G, Benson, G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102: 111–122.
Google Scholar | Crossref | Medline18. Aledort, LM . Deaths associated with emicizumab in patients with hemophilia A. New Engl J Med 2019; 381: 1878–1879.
Google Scholar | Crossref | Medline19. Makris, M, Iorio, A, Lenting, PJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost 2019; 17: 1269–1272.
Google Scholar | Crossref | Medline20. Santagostino, E, Young, G, Escuriola Ettingshausen, C, et al. Inhibitors: a need for eradication? Acta Haematol 2019; 141: 151–155.
Google Scholar | Crossref | Medline21. Collins, PW, Liesner, R, Makris, M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO inhibitor working party and executive committee. Haemophilia 2018; 24: 344–347.
Google Scholar | Crossref | Medline22. Oldenburg, J, Young, G, Santagostino, E, et al. The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Rev Hematol 2018; 11: 857–862.
Google Scholar | Crossref | Medline23. Yada, K, Nogami, K. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations. J Blood Med 2019; 10: 171–181.
Google Scholar | Crossref | Medline24. Kreuz, W, Escuriola Ettingshausen, C, Vdovin, V, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia 2016; 22: 87–95.
Google Scholar | Crossref | Medline25. Hall, GW, Wilkinson, A, Mathias, M, et al. Immune tolerance induction with simoctocog alfa in patients with haemophilia A: an ongoing multicentre case series from the UK. Res Pract Thromb Haemost 2020; 4(Suppl.1): abstract PB1047.
Google Scholar26. Sholzberg, M, Floros, G, Teitel, J. Successful immune tolerance induction with von Willebrand factor containing concentrate in an adult with haemophilia A and chronic inhibitor - a case study. Haemophilia 2016; 22: e99–e118.
Google Scholar | Crossref | Medline27. DiMichele, DM, Hoots, WK, Pipe, SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13: 1–22.
Google Scholar | Crossref28. Iorio, A, Blanchette, V, Blatny, J, et al. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15: 2461–2465.
Google Scholar | Crossref | Medline29. Hajducek, DM, Chelle, P, Hermans, C, et al. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. Haemophilia 2020; 26: 384–400.
Google Scholar | Crossref | Medline30. Morfini, M, Haya, S, Tagariello, G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606–612.
Google Scholar | Crossref | Medline | ISI31. de Visser, MC, Rosendaal, FR, Bertina, RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271–1276.
Google Scholar | Crossref | Medline | ISI32. Rietveld, IM, Lijfering, WM, Le Cessie, S, et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 2019; 17: 99–109.
Google Scholar | Crossref | Medline33. Adam, SS, Key, NS, Greenberg, CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113: 2878–2887.
Google Scholar | Crossref | Medline | ISI34. Coppola, A, Margaglione, M, Santagostino, E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809–1815.
Google Scholar | Crossref | Medline | ISI35. Lapalud, P, Rothschild, C, Mathieu-Dupas, E, et al. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A. J Thromb Haemost 2015; 13: 540–547.
Google Scholar | Crossref | Medline36. Suzuki, T, Arai, M, Amano, K, et al. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749–754.
Google Scholar | Crossref | Medline | ISI37. Tagariello, G, Zanotto, D, Radossi, P, et al. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007; 82: 460–462.
Google Scholar | Crossref | Medline38. Salvagno, GL, Astermark, J, Ekman, M, et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51–56.
Google Scholar | Crossref | Medline | ISI39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use . ICH Harmonised Tripartite Guideline, E3: Structure and Content of Clinical Study Reports. Available at: https://database.ich.org/sites/default/files/E3_Guideline.pdf (accessed 25 February 2021).
Google Scholar40. Giangrande, PLF, Hermans, C, O’Mahony, B, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis 2018; 13: 66.
Google Scholar | Crossref | Medline41. Hay, CR, DiMichele, DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335–1344.
Google Scholar | Crossref | Medline | ISI42. Batsuli, G, Zimowski, KL, Tickle, K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 2019; 25: 789–796.
Google Scholar | Crossref | Medline43. Warren, BB, Thornhill, D, Stein, J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study. Blood Adv 2020; 4: 2451–2459.
Google Scholar | Crossref | Medline44. Manco-Johnson, MJ, Abshire, TC, Shapiro, AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–544.
Google Scholar | Crossref | Medline | ISI45. Gamal Andrawes, N, Hashem Fayek, M, Salah El-Din, N, et al. Effect of low-dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A. Haemophilia 2019; 26: 325–332.
Google Scholar | Crossref | Medline46. Muto, A, Yoshihashi, K, Takeda, M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124: 3165–3171.
Google Scholar | Crossref | Medline47. Samuelson Bannow, B, Recht, M, Négrier, C, et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev 2019; 35: 43–50.
Google Scholar | Crossref | Medline